Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025

Issuer

Circio Holding ASA

* Circio will present its circVec expression platform at the European Society
of Gene and Cell Therapy (ESGCT) annual meeting, taking place on 7-10
October 2025 in Seville, Spain
* In the presentation, Circio will summarize the most recent development of
circVec-AAV in vivo demonstrating significant advantages over conventional
AAVs in heart and other tissues
* ESGCT is one of the most prestigious and widely attended international
conferences in the gene and cell therapy field

Oslo, Norway 1 October 2025 -- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation
nucleic acid medicine, today announces that the European Society of Cell and
Gene Therapy (ESGCT) has selected a Circio abstract for poster presentation at
its annual meeting 2025. The presentation will detail how Circio is enhancing
gene and cell therapy using circVec, its circular RNA vector expression
technology. Specifically, Circio will summarize recent in vivo results
demonstrating significant advantages of its circVec-AAV platform over
conventional AAVs in heart and other tissues.

"Circio s most recent in vivo results continue to demonstrate circVec s strong
potential as a novel expression system for enhanced gene and cell therapy. The
prestigious ESGCT annual meeting provides an excellent opportunity for us to
showcase our latest pre-clinical data to a wide industry and academic
audience," said Dr. Thomas B. Hansen, CTO of Circio. "At this year s
conference, we will present the major advances we have made to enhance
conventional AAV gene therapy using the circVec platform, showing
statistically significant increases in expression in multiple tissues for
several circVec-AAV variants."

Title of presentation:
CircVec: Enhancing gene and cell therapy using circular RNA vector expression
technology (poster no. 1041)

Presenter:
CTO Dr. Thomas B Hansen & CSO Dr. Victor Levitsky

Time:
14:00hrs CEST, 8 October 2025

Location:
Fibes, Seville, Spain

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]

Neil Hunter -- Hunter PR
Phone: +44 782 125 5568
Email: [email protected]

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

More information:
Access the news on Oslo Bors NewsWeb site